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Conjunctival Intraepithelial Neoplasia: A Case Report
Abstract
Background
Background: Gelatinous, vascularized lesions of the conjunctiva are a subset of ocular surface tumors
that are derived from various cell types. The more worrisome origins include diagnoses of conjunctival
intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC). Topical treatments such as
mitomycin-C, 5-fluorouracil, and interferon alfa-2b are now used as single therapy or in conjunction with
surgical excision.
Case Report
Report: This case features a 78-year-old Caucasian male with CIN treated with surgical removal and
topical interferon alfa-2b. In addition to discussing the details of this case, this report highlights important
caveats of the treatment and management of the condition as well as a review of ocular surface
squamous neoplasia.
Conclusion
Conclusion: Clinical observation of a conjunctival lesion can assist with determining severity and includes
documentation of the size, shape, and consistency of the lesion, presence of a feeder vessel (indicating a
more advanced ocular surface lesion), and anatomical location. The clinician can determine if the lesion
is wholly within the conjunctiva or fixed to the globe by simple physical manipulation of it.Gonioscopy can
provide the clinician with information regarding intraocular angle and posterior cornea involvement.
Additional testing such as B-scan, anterior segment OCT, and MRI can provide additional information
about the invasiveness of such lesions. Depending on the surgeon’s preference, excision and cryotherapy,
topical monotherapy, or a combination treatment may be used in these cases. Prognosis is favorable in
most cases if treated early and there is limited recurrence.
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INTRODUCTION
Conjunctival lesions are classified as congenital or acquired groups.1 All
conjunctival lesions combined tend to affect men and women equally.2 However,
there is a preponderance of conjunctival squamous cell carcinoma (SCC),
papilloma, conjunctival nevus, and pingueculae or pterygium types that affect
males.2,3 Conjunctival lesions predominantly present in Caucasian populations.2
Ocular surface squamous neoplasia (OSSN) includes a spectrum of lesions
originating from corneal and conjunctival epithelium, including epithelial
dysplasia, intraepithelial neoplasia, and SCC.1,3-5 Risk factors include: ultraviolet
light exposure, older age, light skin pigmentation, tobacco smoker, occupational
petroleum exposure, human papilloma virus (HPV) infection, human
immunodeficiency virus (HIV) seropositivity, xeroderma pigmentosa, and vitamin
A deficiency.1,3,4,6,7 The gold standard treatment of OSSN lesions involves surgical
excision using a no-touch method demonstrated by Shields.8,9 While the traditional
treatment plan for OSSN lesions involves excision, removal, and biopsy, topical
treatments in conjunction with the no-touch excision or as single therapy have
emerged.
CASE REPORT
INITIAL PRESENTATION
A 78-year-old Caucasian male presented for his first visit to the Department of
Veterans Affairs (VA) eye clinic for an opinion regarding the possibility of a
recurring tumor on his left eye. The patient noted a lesion that was gradually
growing over the past three months on his left conjunctiva. He denied any changes
in vision, headaches, dizziness, diplopia, or eye pain. The patient revealed an ocular
history of excision and cryotherapy for a conjunctival lesion in the same area on
July 2, 2013. No biopsy results were available. The patient had last followed up
with his oculoplastic specialist on July 17, 2014 but was lost to follow-up for that
condition following a cross-country move.
This patient had a complicated ocular history for which he was managed outside
of the VA system. He brought hard-copy documentation of his previous
examination and medical records. Ocular history revealed severe stage primary
open-angle glaucoma OS>OD status-post trabeculectomy OS, cataract extraction
OU, and non-exudative age-related macular degeneration OU. His ocular
medications included Combigan® (brimonidine tartrate/timolol maleate
0.2%/0.5%) every morning OD, latanoprost 0.005% at bedtime OD, and
dorzolamide twice daily OD (While the management of these ocular conditions is
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pertinent to the individual, it has less relevance to this case report, and therefore,
will not be discussed in-depth.). The patient’s family history was positive for
glaucoma; he stated his mother and brother were both diagnosed with the condition.
His medical history was positive for hyperlipidemia, impaired fasting glucose,
gastroesophageal reflux disease, hypertension, neoplasm of prostate, and chronic
kidney disease. His current systemic medication included hydrochlorothiazide 25
mg/triamterene 37.5 mg, terazosin HCL 2 mg, simvastatin 20 mg, lisinopril 40 mg,
and potassium chloride 10 meq. He was oriented to person, place, and time.
The patient’s best corrected visual acuities were 20/20 OD and 20/50+ OS with a
spectacle prescription of -0.75 -2.00 x 093 OD and -0.75 -1.25 x 102 OS. There
was no improvement with pinhole OS. This visual acuity was stable from his
previous examinations. Motilities were full and smooth in all gazes OU. No pain or
diplopia on eye movement was noted. Cover test demonstrated orthophoria at
distance and four prism diopters of exophoria at near. Confrontation visual fields
revealed inferior constriction OD and OS. Pupils were equal, round, and reactive to
light with a 1+ relative afferent pupillary defect (RAPD) OS. Amsler grid testing
revealed no metamorphopsia nor scotoma OD; however, metamorphopsia
inferiorly OS was reported.
Anterior segment evaluation of the OD revealed normal lid appearance, clear and
intact cornea, clear and quiet conjunctiva, deep and quiet anterior chamber, and
mild iris atrophy superiorly. Anterior segment evaluation of the OS revealed normal
lid appearance, corneal pannus inferiorly, a vascularized conjunctival lesion
superior-nasally with overlap onto the cornea extending 3 mm (total lesion size
measured at 6.7 x 7.5 mm, Figure 1), a shallow, avascular bleb superior-temporally,
deep and quiet anterior chamber, and flat iris. Physical manipulation of the
conjunctival lesion showed movement without fixation to the globe. No obvious
feeder vessel was observed. Intraocular pressures were measured at 9:45AM using
Goldmann applanation tonometry at 19 mm Hg OD and 19 mm Hg OS; with
massage of OS, the pressure was decreased to 12 mmHg, which may suggest the
bleb may be under-filtering. Gonioscopy showed visible ciliary body in all
quadrants OU with 1+ pigmentation inferiorly OU; there was no observation of
intraocular invasion by the conjunctival lesion OS. Posterior chamber intraocular
lenses were clear and centered OU. Central corneal thickness was measured as 563
microns OD and 575 microns OS. The patient was dilated using one drop of 1%
tropicamide OU.
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FIGURE 1: Anterior segment image OS. The image displays the vascularized conjunctival lesion
superior-nasally with extension onto the superior cornea.

The differential diagnoses to consider for the conjunctival lesion in this case
include:
• Conjunctival intraepithelial neoplasia (CIN) – This will generally manifest
as a white, gelatinous, usually stalk-like lesion near the limbus with
vascularization.
• Squamous papilloma – This will generally have a sessile, red, gelatinous
appearance in adults, and is commonly associated with human papilloma
virus 16 and 18.
• Squamous cell carcinoma (SCC) – This will generally manifest as a red,
gelatinous mass, typically in the interpalpebral region with possible
extension onto the cornea with a feeder vessel present.
A thorough evaluation was performed to establish a baseline as this was the
patient’s first visit. Posterior segment evaluation demonstrated vitreous syneresis
with complete posterior vitreous detachment OU. The optic discs displayed
generalized minimal rim tissue OU. A cup-to-disc ratio of 0.80 round was
documented with minimal rim tissue inferiorly, and a Drance hemorrhage was
observed inferior-temporally OD. The optic nerve OS displayed a cup-to-disc ratio
of 0.90 without visible rim tissue inferiorly and minimal rim tissue superiorly; optic
nerve head pallor was observed OS. A significant mix of hard and soft drusenoid
changes without the presence of a choroid neovascular membrane (CNVM) was
visible in the macula OU. Retinal blood vessels demonstrated a normal ratio of 2/3
OU, and the peripheral retina was intact with no holes, tears, or detachments 360°
noted OU. Fundus photographs (Figures 2 & 3) and optical coherence tomography
(OCT, Figures 4 & 5) were ordered and performed the same day.
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FIGURE 2: a side-by-side optic nerve head (ONH) image of OD and OS. The images display the
minimal rim tissue of each optic nerve as well as the Drance hemorrhage inferior-temporally to the
ONH OD (yellow arrow).

FIGURE 3: a side-by-side macula image of OD and OS. The images display Age Related Eye
Disease Study (AREDS) category 3 non-exudative macular degeneration changes. No CNVM was
observed in either eye.
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FIGURE 4: an ONH and retinal nerve fiber layer (RNFL) analysis of OD and OS. The average RNFL
thickness is 64 microns OD and 57 microns OS. The vertical cup-to-disc ratio is measured at 0.81
OD and 0.78 OS. Superior thinning can be observed OD with superior and inferior thinning observed
OS.
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FIGURE 5: a macula thickness image OD and OS. The central thickness is measured at 228
microns OD and 214 microns OS. Drusenoid changes are apparent OU.

Given our patient’s history and findings, he was diagnosed with a conjunctival
neoplasm with high suspicion for conjunctival intraepithelial neoplasia OS. The
patient was extensively counseled regarding the findings and the need for an ocular
oncology referral. A consultation was placed with the nearby VA Medical Center.
Additionally, the patient was diagnosed with severe stage primary open-angle
glaucoma OU. This assessment was reached based on the hard-copy Humphrey
visual field (HVF) records the patient brought with him the day of the examination.
A goal IOP of 14 mm Hg OU was previously established by the outside provider.
As this patient was not at goal, the patient was given a drop regimen sheet and his
medications were updated to the VA formulary drops: latanoprost qhs OU,
dorzolamide/timolol bid OD, and brimonidine tid OD. The patient was also
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diagnosed with AREDS category 3 non-exudative age-related macular
degeneration (ARMD) OU. AREDS recommendations were reviewed, and he was
given an Amsler grid and started on AREDS 2 supplementation. The patient chose
to continue his care with his outside eye care provider for glaucoma and ARMD
management.
VA MEDICAL CENTER APPOINTMENT
The patient’s conjunctival lesion was evaluated at the VA Medical Center
following his initial presentation. He was referred to the Kellogg Eye Center
Department of Ocular Oncology for excision and biopsy of the conjunctival lesion
with a presumed diagnosis of conjunctival intraepithelial neoplasia.
KELLOGG EYE CENTER APPOINTMENT
The patient presented to the Kellogg Eye Center for treatment by the ocular
oncologist. Absolute alcohol was applied to the corneal epithelium 2 mm anterior
to the lesion with a weck-cell soaked in alcohol. Excision biopsy of the corneal
lesion with lamellar keratoplasty of left eye was performed. The lesion was
dissected from the cornea with a no-touch technique. Single freeze-thaw
cryotherapy of the cornea of the left eye at the limbus was performed. Excision of
the left inferior and superior limbal conjunctiva with underlying sclera was
performed. Double thaw cryotherapy of the left inferior limbal conjunctiva was
performed. Following the procedures, the patient was given a prescription for
topical interferon alfa-2b 1 million units/Ml four times daily in the left eye with
bottle replacement every 14 days.
A non-formulary request for the topical interferon alfa-2b 1 million units/Ml was
required prior to the medication release. Upon the request’s approval, the
medication was compounded at a specialty pharmacy and given to the patient to be
used four times daily OS. The patient was followed regularly after completion of
the excision. Biopsy results confirmed the diagnosis of conjunctival squamous cell
carcinoma in-situ (CIN Grade III/III).
EYE CLINIC VISIT #2
The patient presented to the VA eye clinic for a second visit for an anterior
segment check following the recent appointment with the Kellogg Eye Center. The
patient was status-post excision and cryotherapy. The patient, under the care of
Kellogg Eye Center, also had received four sub-Tenon’s interferon injections
between October 2015 and January 2016. Post-operative reports showed a decrease
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in vision OS to 20/70-2 without improvement on pinhole. He had two more
appointments scheduled for May and June 2016.
Corrected visual acuities at this visit were 20/20- OD and 20/200-2 OS with
habitual correction. There was no improvement with pinhole OS. External
evaluation had not changed.
Anterior segment evaluation of the OD was the same as his last visit, while the
OS showed dense superficial punctate staining from medicamentosa which covered
the entire cornea. The vascularized, gelatinous lesion was entirely excised and
showed no signs of recurrence. Intraocular pressures measured at 11:08AM using
Goldmann applanation tonometry were 13 mm Hg OD and 12 mm Hg OS, which
were achieving the goal IOP of 14 mm Hg OD/OS. The reduction in IOP was
attributed to the medication changes that had occurred at the initial examination
and improved patient compliance.

Figure 6: an anterior segment image OS. The image displays the resolution of the CIN III/III lesion
following excision and cryotherapy

The patient was instructed to continue the current course of action with his topical
interferon alfa-2b qid OS, discarding the bottle every 14 days. The patient was
educated on keratitis and the high risk for limbal stem cell deficiency given his
surgical history. The patient was educated that surgical procedures (with and
without cryotherapy) can cause ocular surface toxicity, cicatricial conjunctival
changes, and limbal stem cell deficiency. The keratitis was the cause of his reduced
visual acuity and was related to the interferon alfa-2b use, and he was given a
prescription for preservative-free artificial tears to be used qid OS. Strict instruction
was given to separate drops by 10 minutes to avoid any diluting effects. The patient
declined dilation, and an undilated viewing showed stable findings. A follow-up
appointment was scheduled for one week for an anterior segment check OS.
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EYE CLINIC VISIT #3
The patient presented to the VA eye clinic for an anterior segment check.
Corrected visual acuity was 20/20- OD and 20/70-2 OS with habitual correction.
There was no improvement with pinhole OS. External evaluation had not changed.
Anterior segment evaluation of OD and OS were the same as the previous visit.
Intraocular pressures were measured using Goldmann applanation tonometry at 12
mm Hg OD and 11 mm Hg OS, which were under his goal IOP (14 mm Hg
OD/OS). The patient declined dilation, but the undilated viewing showed stable
findings.
The patient was instructed to continue the current course of action with his topical
interferon alfa-2b qid OS, discarding the bottle every 14 days. The patient was
instructed to use the preservative-free artificial tears as needed OS, paying special
attention to separating drops OS by at least 10 minutes to avoid dilution. The patient
was instructed to continue care with his ocular oncologist as scheduled, and he was
scheduled for a six month return to the VA eye clinic for an anterior segment check.
DISCUSSION
The bulbar conjunctiva is a common location of conjunctival tumors and lesions.
The surface consists of non-keratinized stratified squamous epithelial tissue atop
the basement membrane with loose lamina propria below, which helps keep the
conjunctiva attached to the episclera-sclera complex.1,4
Conjunctival tumors and lesions are often separated into two large groups:
congenital and acquired. Shields et al. reported that congenital conjunctival tumors
in the United States account for 2% of the total biopsied conjunctival lesions.2
Acquired conjunctival tumors and lesions are further subcategorized into different
types based on their origin.1 Ocular surface tumors are derived from epithelial,
melanocytic, and lymphocytic cells, and surface epithelial, melanocytic, and
lymphoid tumors are the three most common categories of acquired conjunctival
tumors.1-2 Shields et al. reported that 11% of patients presented with premalignant
and malignant epithelial conjunctival lesions, 53% presented with a melanocytic
conjunctival lesion, and 8% presented with a lymphoid conjunctival lesion.2
Interestingly, 13% of patients in the study were diagnosed with a non-neoplastic
conjunctival lesion, where 22% of those patients had a final diagnosis of
pingueculum, and 13% had a final diagnosis of pterygium.2
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As a whole, conjunctival lesions affect men and women about equally; however,
certain types will predominantly affect males.2 Conjunctival squamous cell
carcinoma, papilloma, conjunctival nevus, and pingueculae or pterygium tend to
affect males at a much higher rate.2,3 Conjunctival lesions typically appear
unilaterally; however, lymphoid tumors are unique in that they appear bilaterally
37% of the time.2,3 Conjunctival lesions predominantly present in Caucasian
populations.2 Shields et al. reported 89% of the conjunctival lesion patients in their
study were Caucasian.2 The bulbar conjunctiva is ultimately the most common area
of conjunctival lesion development.2 Seventy-five percent of all conjunctival
tumors originate at the bulbar conjunctiva, and the nasal and temporal aspects of
the bulbar conjunctival were the most affected with a frequency of 31% and 33%
respectively.2 Conjunctival epithelial tumors frequently present at the limbal or
extralimbal regions, 65% and 28% of the time respectively.2 Melanocytic tumors
appear on the bulbar conjunctiva in 79% of the case. Lymphoid tumors appear in
the fornix or on the bulbar conjunctiva, 37% and 33% of the time respectively.2
Ocular surface squamous neoplasia is a catch-all term that includes lesions
originating from corneal and conjunctival epithelium, including squamous
papilloma, conjunctival intraepithelial neoplasia, and SCC.1,3-5 OSSN has an
incidence of 0.02-3.5 per 100,000.1 A study within the Department of Veterans
Affairs from March 1, 2007 to March 1, 2012 found 28 confirmed cases of OSSN
out of 24,179 patients in a Miami area/South Florida Veterans Affairs Hospital
population.10 The prevalence was measured at 0.1%, and the risk factors determined
for this population were similar to those previously listed.10 If a pterygium was
present, the patient had a 16-fold risk increase of OSSN development.10 There is a
greater frequency of OSSN in individuals who reside closer to the equator because
of increased ultraviolet (UV) light exposure.1,6 Interestingly, according to Gichuhi
et al., 16 south is the latitude with the highest incidence.4 Other risk factors
include: older age, light skin pigmentation, tobacco smoker, occupational
petroleum exposure, human papilloma virus (HPV) infection, human
immunodeficiency virus (HIV) seropositivity, xeroderma pigmentosa, and vitamin
A deficiency.1,3,4,6,7 HIV testing should be considered in younger patients with
OSSN presentations, especially those with a feeder vessel observed.5 Interestingly,
the ATP-binding cassette subfamily B member 5 (ABCB5) gene is upregulated in
cases of OSSN and could possibly be involved in the development of the
condition.11 The ABCB5 gene was observed in several cancer cells, though its
purpose is not well understood at this time.11
Squamous papillomas appear as benign sessile or pedunculated lesions that tend
to appear near the limbus and have the potential to spread to the cornea.1 Sessile
papillomas tend to appear in adults and are commonly associated with HPV 16 and
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18. Typically, these lesions will appear on the bulbar conjunctiva and will have a
broad base from which a fibrovascular frond spreads.1,12 Recurrence of this type of
lesions is possible. Pedunculated lesions tend to appear in children and are
associated with HPV 6 and 11. They generally appear in the inferior fornix and
have a narrow base and many fronds. Recurrence of pedunculated lesions is much
higher than sessile lesions, which are commonly found in adults. The reported
recurrence rate of squamous papilloma in general is 6-27%.1
Interestingly, Tulvatana et al. did not find enough evidence in their study to
conclude that HPV is a risk factor for OSSN.6 HPV association can be considered
non-conclusive, though, because a study by Scott et al., demonstrated the presence
of HPV 16 or 18 being found in each of their CIN subjects.7
CIN has an incidence of 1.9-2/100,000.7,12 They present as gelatinous lesions that
typically appear in fair-skinned individuals 60-70 years old.1,12 The lesion can show
leukoplakia (otherwise known as keratinization), and generally have a sessile
appearance.1,12 CIN has varying grades and levels of dysplasia. Mild dysplasia, or
grade I, ranges from 33% to 50% of corneal or conjunctival epithelial involvement.
Grade II involves more than 50% of the corneal or conjunctival epithelium and is
considered moderate dysplasia. Grade III, commonly called carcinoma in-situ
(CIS), has an incidence of 39%. CIS is severe dysplasia involving the entire
epithelial thickness but without penetration of the basement membrane.1,12,13
SCC is considered invasive, as the cells have penetrated the basement membrane.1
SCC has an incidence of 0.02-3.5 per 100,000.3 SCC displays an exophytic growth
pattern, which is a pattern of growth that occurs in the interpalpebral fissure (as
opposed to endophytic growth, which is another growth pattern, where the other
surrounding tissues of the cornea, sclera, globe, and posterior orbit can become
involved).1,12 Othman reported intraocular invasion occurring 2-15% of the time
and orbital invasion occurring 12-16% of the time.1 SCC metastases are seen in
about 1% of cases.12
Clinical observations can assist with determining severity of the lesion. Similar to
other suspicious lesions of the body, size, shape, and consistency are important to
document. The presence of a feeder vessel may indicate a more advanced ocular
surface lesion. The anatomical location of the lesion provides useful information
about the lesion. The clinician can determine if the lesion is wholly within the
conjunctiva or fixed to the globe by simple physical manipulation of it.1
Gonioscopy provides the clinician with information regarding intraocular angle and
posterior cornea involvement and is important in cases where the lesion shows
corneal involvement. Using B-scan or magnetic resonance imaging with
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gadolinium using 2 mm slices may offer additional information in cases of deep
ocular or periocular metastatic lesions. Lymph nodes should be routinely checked
for any possible involvement while keeping in mind that metastasis is rare.
Preauricular and cervical lymph node involvement may be present in cases of
advanced malignancy. Impression cytology, a process that allows for collected cells
to be studied histologically, is another tool that can be useful in screening patients;
it has a high positive predictive accuracy of 97.4% but a negative predictive
accuracy of 52.9%.1
Mittal et al., reported 142 microns as being the differentiating thickness
measurement between pterygium and OSSN with high sensitivity and specificity.14
The average thickness in OSSN is measured at 346 microns, and the average
pterygium thickness is measured at 101 microns.28 Anterior segment OCT imaging
can assist with the measurement through the use of the caliper function.
Traditionally, the gold standard treatment of OSSN lesions involves surgical
excision using a no-touch method demonstrated by Shields.8,9 The technique does
not use balanced salt solution for surgical irrigation with the intent to avoid
spreading tumor cells associated with the OSSN lesion to other locations on the
globe. The no-touch technique involves creating a 4 mm clinically tumor-free area.
Absolute alcohol and cryotherapy are used during the surgical process.1,15
Reconstruction of the cornea may require lamellar keratoplasty, as had occurred in
this case report, or conjunctival grafts.1 The literature reports variable recurrence
rate of OSSN lesion (widely due to its dependence on positive or negative margins).
Peksayar et al. lists a recurrence rate of 30-40% following surgical excision. Nanji
et al. lists a recurrence rate of up to 56% with positive surgical margins.1,16 Even
OSSN excisions with negative surgical margins have a recurrence rate of up to 33%
and as low as 5%.1,9 Li et al. report a 7.1% recurrence rate at 1 year, 2 years, and 5
years following excision and cryotherapy treatment.9 In extreme cases of advanced
and aggressive ocular or orbital invasion, enucleation or exenteration may be
required.15
Following excision of the OSSN lesion, the use of an amniotic membrane (such
as the brand, Prokera®) may be considered for use to assist with the reconstruction
of the damaged ocular surface.17 An amniotic membrane in an excision situation
provides the removal zone with a covering while helping to reduce inflammation,
vascularization, and scarring by limiting fibrosis that would otherwise occur.1,17
While the traditional treatment plan for OSSN lesions involves excision, removal,
and biopsy, topical treatments either in conjunction with the no-touch method, or
as single therapy, have emerged. Topical options include: mitomycin C, 5-
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fluorouracil (5-FU), and interferon-2b. Mitomycin-C is an alkylating antibiotic,
which essentially damages DNA during all cell-cycle phases and causes irreversible
cross-linking and nucleotide synthesis inhibition.16,18 Rapidly dividing cells are
most sensitive during mitomycin-C use.1 Topical mitomycin-C comes in two
concentrations, 0.02% or 0.04%, with differing dosing schedules.1,16,18 Ocular
toxicity is commonly reported with mitomycin-C use and includes keratitis,
conjunctival hyperemia, ocular allergy, and general irritation.1,16,18 Use of 0.02%
mitomycin-C appears to be related to decreased toxicity.18 Mitomycin-C
monotherapy has demonstrated complete resolution in up to 90% of patients.18,19 5FU is an antimetabolite pyrimidine analogue, which inhibits DNA & RNA
synthesis.16,18,19 5-FU comes in a 1% concentration.16,18 Ocular toxicity is reported
with the use of 5-FU, including hyperemia and keratitis; however, the toxicityrelated issues are not as severe as mitomycin-C use.16,18,19 In a study by Joag et al.,
82% of patients treated with 5-FU monotherapy showed completed resolution.19
Interferon-2b is created from systemic interferon-, which has approval by the
U.S. Food and Drug Administration to treat chronic hepatitis B and C, condylomata
acuminata (HPV-related), malignant melanoma, follicular lymphoma, autoimmune
deficiency syndrome-related Kaposi’s sarcoma (1 or 27 AIDS-defining condition),
and hairy cell leukemia.1,16,18 Interferon-2b is a glycoprotein molecule, which
shows antiviral and antitumor activity by acting on cell surface receptors through a
poorly understood mechanism of action.1,16,18 Topical interferon-2b is
concentrated to 1 million IU per ml.1,16 Galor et al. showed no clinical advantage
to using 3 million IU per ml instead of 1 million IU per ml.20 Compared with
mitomycin-C and 5-FU, interferon-2b shows little ocular toxicity-related side
effects, though keratitis can occur.1,16,18 Interferon-2b can be used as dual-therapy
in an injection delivery system plus topical treatment, as was used in this case
report.16 Shields et al. reported tumor control in 95% of patients when interferon2b is used as monotherapy or combined with surgical excision.21 Karp et al. and
Kusumesh et al. showed complete CIN resolution with monotherapy use of topical
interferon-2b.22,23 The use of interferon-2b when combined with surgical
excision may improve outcomes, especially in cases where a negative tumor margin
may be difficult to achieve.22,24,25
A study from Moon et al. reported on a cost comparison between interferon-2b
and surgical excision. The interferon-2b presented an average of two more visits
than the surgical group. An average cost increase of $12,612 for surgery compared
to interferon-2b was noted. The cost of office visits was higher in the medical
group because many of the visits in the surgical group were covered within the
global period. Using Medicare allowance, there was no statistical difference
between the surgical and topical options.26 Joag et al., reports cost of $190 per
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month for mitomycin-C, $240 per month for interferon-2b, and $40 per month for
5-FU.19
Mitomycin-C and 5-fluorouracil, two drops that are used in cases of OSSN, have
been related to limbal stem cell destruction and subsequent deficiency. The limbal
region contains stem cells that are responsible for corneal epithelial integrity,
providing for regeneration of those cells. These cells are susceptible to permanent
damage causing a condition referred to as limbal stem cell deficiency (LSCD). In
cases of LSCD, conjunctival cells begin to replace corneal cells. The cornea may
also show signs of ulceration, scarring, neovascularization, or non-resolving
epithelial defects. When staining with fluorescein, a vortex pattern may be observed
along with a poor, unbalanced tear film, corneal erosion, and corneal filaments.
Surgical procedures with limbal involvement (such as trabeculectomy and removal
of conjunctival lesion with corneal involvement) also pose a risk to limbal stem
cells because mitomycin-C is commonly used. Treatment ranges from the use of
preservative-free artificial tears in mild cases of LSCD to limbal grafts in very
severe cases of LSCD where entire limbal integrity is compromised. Taking
advantage of the vault provided by a scleral lens may also benefit a patient suffering
with severe LSCD as it will afford the opportunity for a healing environment.27
CONCLUSION
This case demonstrates the role of case history, clinical observations, and proper
referral in the diagnosis and management of a suspicious conjunctival lesion. It is
important for the clinician to remember that clinical observation can assist with
determining severity of the lesion. Gonioscopy can provide the clinician with
information regarding intraocular angle and posterior cornea involvement. It is
important to perform gonioscopy in cases where the lesion shows corneal
involvement. Additional testing such as B-scan, anterior segment OCT, and MRI
can provide additional information about the invasiveness of such lesions. Similar
to other suspicious lesions of the body, size, shape, and consistency are important
to document. The presence of a feeder vessel may indicate a more advanced ocular
surface lesion. The anatomical location of the lesion provides useful information
about the lesion. The clinician can determine if the lesion is wholly within the
conjunctiva or fixed to the globe by simple physical manipulation of it.1 Depending
on the surgeon’s preference, excision and cryotherapy, topical monotherapy, or a
combination treatment may be used in these cases. Prognosis is favorable in most
cases if treated early and there is limited recurrence.
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